326 related articles for article (PubMed ID: 24309604)
1. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
Wang Z; Li K; Dong K; Xiao X; Zheng S
J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
[No Abstract] [Full Text] [Related]
2. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
3. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
6. Expansile kaposiform hemangioendothelioma deformed thoracic cage in an adult.
Wu CH; Tsai TM; Liau JY; Chang YL; Lai HS; Lee JM
Ann Thorac Surg; 2013 Nov; 96(5):1854-7. PubMed ID: 24182473
[TBL] [Abstract][Full Text] [Related]
7. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
[No Abstract] [Full Text] [Related]
8.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
9. [Kaposiform hemangioendothelioma in a neonate associated with Kasabach-Merritt phenomenon: case report].
Huang X; Wei B; Jiang Y
Zhonghua Er Ke Za Zhi; 2015 Oct; 53(10):790-1. PubMed ID: 26758119
[No Abstract] [Full Text] [Related]
10. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
11. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
12. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
13. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
14. Association between extremity kaposiform hemangioendothelioma and lymphedema.
Konczyk DJ; Goss JA; Maclellan RA; Greene AK
Pediatr Dermatol; 2018 Jan; 35(1):e92-e93. PubMed ID: 29266383
[TBL] [Abstract][Full Text] [Related]
15. [Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon].
Inguanzo-Ortiz M; Piqué-Duran E; Aparicio-Sánchez JL; Vaca-Arellano MR
An Pediatr (Engl Ed); 2018 May; 88(5):292-293. PubMed ID: 29625805
[No Abstract] [Full Text] [Related]
16. Vincristine, actinomycin D, cyclophosphamide chemotherapy resolves Kasabach-Merritt syndrome resistant to conventional therapies.
Fuchimoto Y; Morikawa N; Kuroda T; Hirobe S; Kamagata S; Kumagai M; Matsuoka K; Morikawa Y
Pediatr Int; 2012 Apr; 54(2):285-7. PubMed ID: 22507155
[No Abstract] [Full Text] [Related]
17. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with embolization and vincristine in two newborns.
Garcia-Monaco R; Giachetti A; Peralta O; Napoli N; Lobos P; Gioseffi L; Mariani G
J Vasc Interv Radiol; 2012 Mar; 23(3):417-22. PubMed ID: 22365299
[TBL] [Abstract][Full Text] [Related]
18. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
19. NEWBORNS WITH KASABACH-MERRITT PHENOMENON-ASSOCIATED KAPOSIFORM HEMANGIOENDOTHELIOMA: A REPORT OF 6 CASES.
Benzar IM; Rebenkov SO; Levytskyi AF; Fedoniuk LY; Fomina LV; Sas LM; Stravskyy TY
Wiad Lek; 2020; 73(8):1785-1789. PubMed ID: 33055352
[TBL] [Abstract][Full Text] [Related]
20. Kaposiform Hemangioendothelioma: Multifocal Involvement, Chylothorax, and Kasabach-Merritt Phenomenon.
Das A; Bansal D; Chatterjee D; Das A
J Pediatr Hematol Oncol; 2017 Mar; 39(2):153-154. PubMed ID: 27820128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
